Advertisement

Volume 133, Issue 14

 

 

April 4, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Vascular and cardiac toxicity of ponatinib due to VWF-mediated platelet adhesion. See the article by Latifi et al.

The von Willebrand factor D’D3 assembly and structural principles for factor VIII binding and concatemer biogenesis
In this Plenary Paper, the investigators report a significant advance in our understanding of von Willebrand factor (VWF) structure and the interaction of VWF with factor VIII. They describe the first high-resolution crystal structure of the monomeric D’D3 assembly of human VWF and the additional structural implications for hundreds more proteins that contain von Willebrand disease domains.


Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib
Using a mouse model, the investigators address the critical question of the vascular and cardiac toxicity of the BCR-ABL tyrosine kinase inhibitor ponatinib. Their experiments reveal that ponatinib vascular toxicity is due to VWF-mediated platelet adhesion.


Myeloma bone disease: from biology findings to treatment approaches
Bone disease remains a challenge in the therapeutic management of myeloma. This concise Blood Spotlight examines the current status of research on the biology of myeloma bone disease and its treatment.


How I treat early-relapsing follicular lymphoma
In this How I Treat article, 2 leaders in the field offer thorough and comprehensive guidance regarding the recommended approach to managing patients with early-relapsing follicular lymphoma, an area where there is currently no clear standard of care. The authors selected clinical vignettes that are representative of the patients whom we see in clinical practice.


A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
This paper reports the results of a large multicenter phase 2 study evaluating an intensified pediatric chemotherapy regimen to treat older adolescents and young adults with Philadelphia chromosome–negative B-cell precursor acute lymphoblastic leukemia.


View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.